We use cookies for a better user experience. Read our Privacy Policy

I Agree

Triclabendazole Market

Triclabendazole Market (Dosage Form: Tablet and Oral Suspension; Animal Type: Cattle, Sheep, Goat, and Others; and Distribution Channel: Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Triclabendazole Market Outlook 2031

  • The global triclabendazole market was valued at US$ 412 Mn in 2020
  • It is estimated to expand at a CAGR of 4.1% from 2021 to 2031
  • The global triclabendazole market is expected to reach the value of US$ 632.1 Mn by the end of 2031

Analysts’ Viewpoint on Triclabendazole Market Scenario

Telehealth and eHealth services are changing the triclabendazole market landscape amid the ongoing COVID-19 pandemic. However, the launch of vaccines for fasciolas species is affecting sales of triclabendazole therapeutics. Hence, healthcare companies in the veterinary segment should tap revenue opportunities and diversify their focus on dairy and protein products sector. While using triclabendazole, veterinarians are educating animal owners to choose efficient treatment plans for using drugs that target the stage of the disease. It has been found that triclabendazole is relatively effective against the very early stages of the infection in animals.

Requirement for Quality Dairy and Meat Products Triggers Demand for Triclabendazole Therapeutics

The ever-expanding dairy industry is creating revenue opportunities for companies in the triclabendazole market. The high demand for quality milk and protein products is translating into revenue opportunities for triclabendazole medicine manufacturers. As such, manufacturers are increasing output capacities in the form of tablet and oral suspensions.

Cost-effective production of safe and high quality animal protein is necessary to meet consumer needs. Healthcare companies in the triclabendazole market are taking advantage of this trend to increase the availability of therapeutics in veterinary hospitals, clinics, pharmacies, and drug stores. Moreover, eCommerce holds promising potentials to expand revenue streams.

To know the scope of our report Get a Sample on Triclabendazole Market

Healthcare Companies Emerge Resilient to COVID-19 Pandemic by Rethinking Supply Networks

Manufacturers in the triclabendazole market are increasing local production capabilities to reduce dependence on other countries for veterinary medical supplies. Manufacturers are working at breakneck speeds to increase the availability for life-saving therapeutics. In the veterinary landscape, elective procedures have been postponed indefinitely. Such findings are affecting revenue generation activities in the triclabendazole market. Nevertheless, manufacturers are ensuring business continuity by maintaining optimum inventory levels.

Companies in the triclabendazole market are rethinking supply networks during the ongoing pandemic, owing to logistic challenges. Although poor demand sentiments are affecting income sources of healthcare companies, participants in the market are establishing balanced relationship with suppliers and ecosystem partners to keep economies running. They are strategizing over marketing and distribution activities to revive revenue sources.

Get a glimpse of the in-depth analysis through our Report Brochure

High Prevalence of Fascioliasis in Animals Creating Precautions for Triclabendazole Medicines

Veterinarians are gaining cognizance about side effects and precautions of triclabendazole such as possible abdominal pain amongst animals and reading the label for non-prescription medicines. Triclabendazole is being extensively used for treating fascioliasis, which is caused by the liver fluke parasite namely fasciola hepatica. The high incidence of animals eating contaminated water plants such as watercress or algae is leading to increased morbidity and mortality in animals due to fascioliasis. Manufacturers are boosting their production capabilities for triclabendazole medications to support treatment of fascioliasis in animals.

Expanding operations in future? To get the perfect launch ask for a custom report

Government Initiatives to Control Liver Fluke Infections Boost Triclabendazole Sales

Government initiatives are contributing to the management of liver fluke infections. Such initiatives are evident in countries such as Western Australia (WA), owing to the absence of liver fluke in the country. Moreover, potential carrier animals imported in WA are subject to mandatory testing. Thus, treatment provisions are being made by maintaining robust supply of triclabendazole medicines to ensure freedom from liver fluke.

The annual cost of liver fluke disease is estimated to be US$ 1 Bn in Australia and US$ 7.11 Bn in Brazil. Hence, manufacturers in the triclabendazole market are ensuring a continuous supply of therapeutics in veterinary healthcare facilities to reduce the treatment burden on the government and other participants in the value chain.

Effective Treatment and Control on Farms with Triclabendazole Improves Clinical Outcomes

Growing awareness about the efficacy of triclabendazole for the treatment of liver fluke disease is contributing to market growth. Healthcare companies in the triclabendazole market are capitalizing on this opportunity to boost production capacities, since this disease causes significant financial losses to producers in value chains such as meat, dairy, and other industries.

Cattle and sheep are fueling the demand for triclabendazole medicines. Veterinarians are educating and creating awareness among animal owners about effective treatment and control on farms by helping them acquire a better understanding of the infection cycle. This is necessary since the weather has a significant effect on the prevalence of liver fluke in cattle and sheep.

Triclabendazole Market: Overview

  • Triclabendazole, a benzimidazole derivative, is one of the most extensively used anthelminthic medications for treating and controlling fascioliasis in cattle and people. It has been demonstrated to reduce the excretion of Fasciola spp. eggs in cow and sheep feces by over 95%. Unlike other anthelminthics, which are only effective against adult flukes, this one is effective against both adults and children.
  • Triclabendazole is effective against adult and immature flukes, which are two weeks old and above. The lethal action against immature flukes is mostly significant, as the passage of the emerging flukes out of the small intestine and into liver is the most risky stage of the infection.
  • Increase in incidence of Faciolas hepatica/liver fluke and rise in awareness about treatment of livestock in the initial phase of the disease using triclabendazole is expected to propel the global triclabendazole market

Triclabendazole Market: Key Drivers

  • Rise in prevalence of liver fluke caused by trematode parasite is anticipated to drive the need of triclabendazole drugs for the treatment of the same
  • Fasciola hepatica, also known as the common liver fluke, occurs in many areas of the world and usually is caused by F. hepatica. In general, fascioliasis is more common and widespread in animals than in people.
  • Liver fluke affects sheep and cattle of all ages and can reduce live-weight gains by 10% in adults and 30% in lambs and calves. The weather has a significant effect on the prevalence of liver fluke, especially mild winters and wet summers. The first step toward more effective treatment and control on farms is to gain a better understanding of the infection cycle and seasonal hazards of liver fluke.
  • A range of products can be used to treat cattle and sheep for fluke. When choosing treatment plans, it is important to use drugs that target the stage most likely to be present within the animal at the time to help reduce selection pressure. Triclabendazole is the only product that is effective against the very early stages, from two weeks after infection to adults.

Market Segmentation: Triclabendazole Market

  • In terms of dosage form, the global triclabendazole market has been bifurcated into tablet and oral suspension
  • Based on animal type, the global triclabendazole market has been classified into cattle, sheep, goat, and others
  • Based on distribution channel, the global triclabendazole market has been divided into veterinary hospitals, veterinary clinics, pharmacies & drug stores, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The triclabendazole market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.

Regional Overview: Triclabendazole Market

  • In terms of region, the global triclabendazole market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global triclabendazole market in 2020, accounting for 30.9% share. Growth of the market in the region can be attributed to high livestock population and increase in spending on preventive healthcare. Rise in prevalence of F. hepatica in sheep and cattle in North America is anticipated to drive the market during the forecast period. Moreover, increase in awareness about the use of triclabendazole in the treatment of Fasciola hepatica infection is expected to boost the growth of the market over the next few years.

Major Players

  • The triclabendazole market report concludes with the company profiles section, which includes key information about major players in the global triclabendazole market
  • Leading players analyzed in the report include
    • AdvaCare Pharma
    • RV Lifesciences Limited
    • Grampus Laboratories
    • Intas Pharmaceuticals Ltd.
    • Shanghai Tongren Pharmaceutical Co., Ltd.
    • Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd.
    • Siflon Drugs & Pharmaceuticals Pvt. Ltd.
    • Elanco
    • Virbac
    • Bimeda, Inc.
    • Chanelle Pharma
    • Zoetis Health
  • Each of these players has been profiled in the triclabendazole market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Triclabendazole Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 412 Mn

Market Forecast Value in 2031

US$ 632.1 Mn

Growth Rate (CAGR)

4.1%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Dosage Form
    • Tablet
    • Oral Suspension
  • By Animal Type
    • Cattle
    • Sheep
    • Goat
    • Others
  • By Distribution Channel
    • Veterinary Hospitals
    • Veterinary Clinics
    • Pharmacies & Drug Stores
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico 
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East &Africa

Companies Profiled

  • AdvaCare Pharma,
  • RV Lifesciences Limited
  • Grampus Laboratories
  • Intas Pharmaceuticals Ltd.
  • Shanghai Tongren Pharmaceutical Co., Ltd.
  • Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd
  • Siflon Drugs & Pharmaceuticals Pvt. Ltd.
  • Elanco
  • Virbac
  • Bimeda, Inc.
  • Chanelle Pharma
  • Zoetis Health
  • Other prominent players.

Customization Scope

Available upon request

Pricing

Available upon request

Triclabendazole Market – Segmentation

TMR’s study on the global triclabendazole market includes information divided into four segments: dosage form, animal type, distribution channel, and region. Changing industry trends and other market dynamics associated with these segments of the global triclabendazole market are discussed in detail.

Dosage Form
  • Tablet
  • Oral Suspension
Animal Type
  • Cattle
  • Sheep
  • Goat
  • Others
Distribution Channel
  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Triclabendazole Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of triclabendazole market?

Triclabendazole market is expected to reach the value of US$ 632.1 Mn by 2031

What is the anticipated CAGR of the triclabendazole market in the forecast period?

Triclabendazole market to expand at a CAGR of 4.1% from 2021 to 2031

What are the key driving factors for the growth of the triclabendazole market?

Triclabendazole market is driven by rise in demand for improved nutrition, particularly animal protein, and increase in focus on food safety.

Which is the rising prominent segment in the triclabendazole market?

The veterinary hospitals segment dominated the market, accounting for 26.4% share in 2020 and the trend is projected to continue during the forecast period.

Who are the key players in the global triclabendazole market?

Key players operating in the global market include AdvaCare Pharma, RV Lifesciences Limited, Grampus Laboratories, Intas Pharmaceuticals Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Triclabendazole Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Triclabendazole Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Prevalence rate of Fasciola hepatica in animal health

    5.2. Sales Volume of Triclabendazole (Best effort Basis)

    5.3. Pricing Analysis

    5.4. Regulatory Scenario by Region/globally

    5.5. COVID-19 Impact Analysis  

6. Global Triclabendazole Market Analysis and Forecast, by Dosage Form

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Triclabendazole Market Value Forecast, by Dosage Form, 2017–2031

        6.2.1. Tablet

        6.2.2. Oral Suspension

    6.3. Global Triclabendazole Market Attractiveness, by Dosage Form

7. Global Triclabendazole Market Analysis and Forecast, by Animal Type

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Triclabendazole Market Value Forecast, by Animal Type, 2017–2031

        7.2.1. Cattle

        7.2.2. Sheep

        7.2.3. Goat

        7.2.4. Others

    7.3. Global Triclabendazole Market Attractiveness, by Animal Type

8. Global Triclabendazole Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Triclabendazole Market Value Forecast, by Distribution Channel, 2017–2031

        8.2.1. Veterinary Hospitals

        8.2.2. Veterinary Clinics

        8.2.3. Pharmacies & Drug Stores

        8.2.4. Others

    8.3. Global Triclabendazole Market Attractiveness, by Distribution Channel

9. Global Triclabendazole Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Triclabendazole Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. North America Triclabendazole Market Attractiveness, by Region

10. North America Triclabendazole Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

        10.2.1. Tablet

        10.2.2. Oral Suspension      

    10.3. North America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

        10.3.1. Cattle

        10.3.2. Sheep  

        10.3.3. Goat

        10.3.4. Others

    10.4. North America Triclabendazole Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Veterinary Hospitals

        10.4.2. Veterinary Clinics

        10.4.3. Pharmacies & Drug Stores

        10.4.4. Others

        10.4.5. North America Triclabendazole Market Attractiveness, by Distribution Channel

    10.5. North America Triclabendazole Market Value (US$ Mn) Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Triclabendazole Market Attractiveness Analysis

        10.6.1. By Dosage Form

        10.6.2. By Animal Type

        10.6.3. By Distribution Channel          

        10.6.4. By Country

11. Europe Triclabendazole Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

        11.2.1. Tablet

        11.2.2. Oral Suspension

    11.3. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

        11.3.1. Cattle

        11.3.2. Sheep

        11.3.3. Goat

        11.3.4. Others      

    11.4. Europe Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        11.4.1. Germany

        11.4.2. U.K.

        11.4.3. France

        11.4.4. Spain

        11.4.5. Italy

        11.4.6. Rest of Europe

    11.5. Europe Triclabendazole Market Attractiveness Analysis

        11.5.1. By Dosage Form

        11.5.2. By Animal Type

        11.5.3. By Distribution Channel

        11.5.4. By Country/Sub-region

12. Asia Pacific Triclabendazole Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

        12.2.1. Tablet

        12.2.2. Oral Suspension

    12.3. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

        12.3.1. Cattle

        12.3.2. Sheep  

        12.3.3. Goat

        12.3.4. Others

    12.4. Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        12.4.1. China

        12.4.2. Japan

        12.4.3. India

        12.4.4. Australia & New Zealand

        12.4.5. Rest of Asia Pacific

    12.5. Asia Pacific Triclabendazole Market Attractiveness Analysis

        12.5.1. By Dosage Form

        12.5.2. By Animal Type

        12.5.3. By Distribution Channel

        12.5.4. By Country/Sub-region

13. Latin America Triclabendazole Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

        13.2.1. Tablet

        13.2.2. Oral Suspension

    13.3. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

        13.3.1. Cattle

        13.3.2. Sheep

        13.3.3. Goat

        13.3.4. Others          

    13.4. Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        13.4.1. Brazil

        13.4.2. Mexico

        13.4.3. Rest of Latin America Latin America

    13.5. Latin America Triclabendazole Market Attractiveness Analysis

        13.5.1. By Dosage Form

        13.5.2. By Animal Type

        13.5.3. By Distribution Channel    

        13.5.4. By Country/Sub-region

14. Middle East & Africa Triclabendazole Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

        14.2.1. Tablet  

        14.2.2. Oral Suspension

    14.3. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

        14.3.1. Cattle

        14.3.2. Sheep  

        14.3.3. Goat

        14.3.4. Others

    14.4. Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

        14.4.1. GCC Countries

        14.4.2. South Africa

        14.4.3. Rest of Middle East & Africa

    14.5. Middle East & Africa Triclabendazole Market Attractiveness Analysis

        14.5.1. By Dosage Form

        14.5.2. By Animal Type

        14.5.3. By Distribution Channel

        14.5.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by Tier and Size of companies)

    15.2. Market Share / Position Analysis, by Company, 2020

    15.3. Competitive Business Strategies

    15.4. Company Profiles

        15.4.1. AdvaCare Pharma

            15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.1.2. Financial Analysis

            15.4.1.3. Growth Strategies

            15.4.1.4. SWOT Analysis

        15.4.2. RV Lifesciences Limited

            15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.2.2. Financial Analysis

            15.4.2.3. Growth Strategies

            15.4.2.4. SWOT Analysis

        15.4.3. Grampus Laboratories

            15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.3.2. Financial Analysis

            15.4.3.3. Growth Strategies

            15.4.3.4. SWOT Analysis

        15.4.4. Intas Pharmaceuticals Ltd

            15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.4.2. Financial Analysis

            15.4.4.3. Growth Strategies

            15.4.4.4. SWOT Analysis

        15.4.5. Shanghai Tongren Pharmaceutical Co., Ltd.

            15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.5.2. Financial Analysis

            15.4.5.3. Growth Strategies

            15.4.5.4. SWOT Analysis

        15.4.6. Shijiazhuang Shimu Animal Pharmaceutical Co., Ltd.

            15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.6.2. Financial Analysis

            15.4.6.3. Growth Strategies

            15.4.6.4. SWOT Analysis

        15.4.7. Siflon Drugs & Pharmaceuticals Pvt. Ltd.

            15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.7.2. Financial Analysis

            15.4.7.3. Growth Strategies

            15.4.7.4. SWOT Analysis

        15.4.8. Elanco

            15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.8.2. Financial Analysis

            15.4.8.3. Growth Strategies

            15.4.8.4. SWOT Analysis

        15.4.9. Virbac

            15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.9.2. Financial Analysis

            15.4.9.3. Growth Strategies

            15.4.9.4. SWOT Analysis

        15.4.10. Bimeda, Inc.

            15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.10.2. Financial Analysis

            15.4.10.3. Growth Strategies

            15.4.10.4. SWOT Analysis

        15.4.11. Chanelle Pharma

            15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.11.2. Financial Analysis

            15.4.11.3. Growth Strategies

            15.4.11.4. SWOT Analysis

        15.4.12. Zoetis Health

            15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.4.12.2. Financial Analysis

            15.4.12.3. Growth Strategies

            15.4.12.4. SWOT Analysis

List of Tables

Table 01: Global Triclabendazole Market Volume (000 Unit) Forecast, by Oral Suspension, 2017–2031

Table 02: Global Triclabendazole Market Volume (000 Unit) Forecast, by Tablet, 2017–2031

Table 03: Global Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 04: Global Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

Table 05: Global Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global Triclabendazole Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: North America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 09: North America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

Table 10: North America Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 11: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 12: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 13: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

Table 14: Europe Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 15: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 17: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

Table 18: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 19: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 21: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

Table 22: Latin America Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 23: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 24: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 25: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Animal Type, 2017–2031

Table 26: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 02: Global Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 03: Global Triclabendazole Market Value (US$ Mn), by Tablet, 2017–2031

Figure 04: Global Triclabendazole Market Value (US$ Mn), by Oral Suspension, 2017–2031

Figure 05: Global Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031

Figure 06: Global Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031

Figure 07: Global Triclabendazole Market Value (US$ Mn), by Cattle, 2017–2031

Figure 08: Global Triclabendazole Market Value (US$ Mn), by Sheep, 2017–2031

Figure 09: Global Triclabendazole Market Value (US$ Mn), by Goat, 2017–2031

Figure 10: Global Triclabendazole Market Value (US$ Mn), by Others, 2017–2031 

Figure 11: Global Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 12: Global Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 13: Global Triclabendazole Market Value (US$ Mn), by Veterinary Hospitals, 2017–2031

Figure 14: Global Triclabendazole Market Value (US$ Mn), by Veterinary Clinics, 2017–2031

Figure 15: Global Triclabendazole Market Value (US$ Mn), by Pharmacies & Drug Stores, 2017–2031

Figure 16: Global Triclabendazole Market Value (US$ Mn), by Others, 2017–2031

Figure 17: Global Triclabendazole Market Value Share Analysis, by Region, 2020 and 2031

Figure 18: Global Triclabendazole Market Attractiveness Analysis, by Region, 2021–2031

Figure 19: North America Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 20: North America Triclabendazole Market Value Share, by Country, 2020–2031

Figure 21: North America Triclabendazole Market Attractiveness Analysis, by Country, 2021–2031

Figure 22: North America Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 23: North America Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 24: North America Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031

Figure 25: North America Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031

Figure 26: North America Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 27: North America Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 28: Europe Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 29: Europe Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031

Figure 30: Europe Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031 

Figure 31: Europe Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 32: Europe Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 33: Europe Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031

Figure 34: Europe Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031

Figure 35: Europe Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 36: Europe Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 37: Asia Pacific Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 38: Asia Pacific Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031

Figure 39: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 40: Asia Pacific Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 41: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 42: Asia Pacific Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031

Figure 43: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031

Figure 44: Asia Pacific Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 45: Asia Pacific Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 46: Latin America Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 47: Latin America Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031

Figure 48: Latin America Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 49: Latin America Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 50: Latin America Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 51: Latin America Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031

Figure 52: Latin America Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031

Figure 53: Latin America Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 54: Latin America Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 55: Middle East & Africa Triclabendazole Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 56: Middle East & Africa Triclabendazole Market Value Share, by Country/Sub-region, 2020–2031

Figure 57: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 58: Middle East & Africa Triclabendazole Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 59: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 60: Middle East & Africa Triclabendazole Market Value Share Analysis, by Animal Type, 2020 and 2031 

Figure 61: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Animal Type, 2021–2031

Figure 62: Middle East & Africa Triclabendazole Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 63: Middle East & Africa Triclabendazole Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

955

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved